Donor safety confirmed
- PMID: 39136968
- PMCID: PMC11372387
- DOI: 10.1182/bloodadvances.2024013477
Donor safety confirmed
Conflict of interest statement
Comment on
-
Long-term outcomes of peripheral blood stem cell unrelated donors mobilized with filgrastim.Blood Adv. 2024 Aug 13;8(15):4196-4206. doi: 10.1182/bloodadvances.2024012646. Blood Adv. 2024. PMID: 38687368 Free PMC article.
References
-
- Stefanski HE, Kuxhausen M, Bo-Subait S, et al. Long-term outcomes of peripheral blood stem cell unrelated donors mobilized with filgrastim. Blood Adv. 2024;8(15):4196–4206. - PubMed
-
- Dührsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood. 1988;72(6):2074–2081. - PubMed
-
- Bennett CL, Evens AM, Andritsos LA, et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the research on adverse drug events and reports (RADAR) project. Br J Haematol. 2006;135(5):642–650. - PubMed
-
- Vasiliu IM, Petri MA, Baer AN. Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares. J Rheumatol. 2006;33(9):1878–1880. - PubMed
-
- Nagler A, Korenstein-Ilan A, Amiel A, Avivi L. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol. 2004;32(1):122–130. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
